• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    12/22/25 5:15:09 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INAB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    IN8BIO, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    45674E208

    (CUSIP Number)


    12/19/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45674E208


    1Names of Reporting Persons

    Stonepine Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,007,990.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,007,990.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,007,990.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The securities beneficially owned by the reporting persons consist of (1) 679,421 shares of Common Stock, and (2) Prefunded Warrants to acquire 929,275 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ending September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Company in a private placement, as reported in the Form 8-K filed by the Issuer on December 19, 2025.


    SCHEDULE 13G

    CUSIP No.
    45674E208


    1Names of Reporting Persons

    Stonepine Capital, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,007,990.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,007,990.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,007,990.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The securities beneficially owned by the reporting persons consist of (1) 679,421 shares of Common Stock, and (2) Prefunded Warrants to acquire 929,275 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ending September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Company in a private placement, as reported in the Form 8-K filed by the Issuer on December 19, 2025.


    SCHEDULE 13G

    CUSIP No.
    45674E208


    1Names of Reporting Persons

    Stonepine GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,007,990.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,007,990.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,007,990.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The securities beneficially owned by the reporting persons consist of (1) 679,421 shares of Common Stock, and (2) Prefunded Warrants to acquire 929,275 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ending September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Company in a private placement, as reported in the Form 8-K filed by the Issuer on December 19, 2025.


    SCHEDULE 13G

    CUSIP No.
    45674E208


    1Names of Reporting Persons

    Jon M. Plexico
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,007,990.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,007,990.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,007,990.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The securities beneficially owned by the reporting persons consist of (1) 679,421 shares of Common Stock, and (2) Prefunded Warrants to acquire 929,275 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ending September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Company in a private placement, as reported in the Form 8-K filed by the Issuer on December 19, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IN8BIO, Inc.
    (b)Address of issuer's principal executive offices:

    350 5th Avenue, Suite 5330, New York, NY 10118
    Item 2. 
    (a)Name of person filing:

    Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Ordinary Shares except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Ordinary Shares covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    45674E208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Stonepine: 1,007,990 Partnership: 1,007,990 General Partner: 1,007,990 Jon M. Plexico: 1,007,990
    (b)Percent of class:

    Stonepine: 9.9% Partnership: 9.9% General Partner: 9.9% Jon M. Plexico: 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (ii) Shared power to vote or to direct the vote:

    Stonepine: 1,007,990 Partnership: 1,007,990 General Partner: 1,007,990 Jon M. Plexico: 1,007,990

     (iii) Sole power to dispose or to direct the disposition of:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Stonepine: 1,007,990 Partnership: 1,007,990 General Partner: 1,007,990 Jon M. Plexico: 1,007,990

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Stonepine Capital Management, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:12/19/2025
     
    Stonepine Capital, L.P.
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
    Date:12/19/2025
     
    Stonepine GP, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:12/19/2025
     
    Jon M. Plexico
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Reporting person
    Date:12/19/2025
    Exhibit Information

    EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

    Get the next $INAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INAB

    DatePrice TargetRatingAnalyst
    3/18/2024$7.50Buy
    Laidlaw
    8/30/2022$14.00Buy
    H.C. Wainwright
    1/24/2022$19.00 → $9.00Buy
    B. Riley Securities
    8/24/2021$12.00Buy
    Mizuho
    8/23/2021$19.00Buy
    B. Riley Securities
    More analyst ratings

    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Rochlin Kate was granted 7,247 shares, increasing direct ownership by 394% to 9,085 units (SEC Form 4)

    4 - IN8BIO, INC. (0001740279) (Issuer)

    12/23/25 6:20:14 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Mccall Patrick was granted 7,247 shares, increasing direct ownership by 324% to 9,482 units (SEC Form 4)

    4 - IN8BIO, INC. (0001740279) (Issuer)

    12/23/25 6:20:12 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT AND CEO Ho William Tai-Wei was granted 36,232 shares, increasing direct ownership by 43% to 121,168 units (SEC Form 4)

    4 - IN8BIO, INC. (0001740279) (Issuer)

    12/23/25 6:20:11 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

    $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio's novel gamma-delta ("γδ") T cell engager through an Investigational New Drug ("IND") application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. ("IN8Bio" or the "Company") (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that it has entered into a definitive securities purchase agreement ("SPA") with certain institu

    12/19/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety profileExpanded Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University, supporting faster enrollment to complete the Phase 1 expansion cohortContinued to advance IN8bio's proprietary γδ T cell platform with ongoing pipeline progression and updated INB-200/400 clinical data in newly diagnosed glioblastoma (GBM) to be presented at the 2025 Society for Neuro-Oncology (SN

    11/6/25 4:00:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

    NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company's INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. The addition of this leading academic institution reflects a strong interest in INB-100 and supports the ongoing efforts to accelerate enrollment and complete this Phase 1 trial. "This trial is an excellent opportunity

    10/29/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    SCHEDULE 13G - IN8BIO, INC. (0001740279) (Subject)

    12/22/25 5:15:09 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - IN8BIO, INC. (0001740279) (Filer)

    12/19/25 5:22:35 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by IN8bio Inc.

    8-K - IN8BIO, INC. (0001740279) (Filer)

    11/24/25 8:00:10 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on IN8bio with a new price target

    Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50

    3/18/24 8:14:30 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on IN8bio with a new price target

    H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00

    8/30/22 7:19:37 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities reiterated coverage on IN8bio with a new price target

    B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously

    1/24/22 9:01:28 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Leadership Updates

    Live Leadership Updates

    View All

    IN8bio Appoints Dr. Corinne Epperly to Board of Directors

    Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex

    12/7/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

    Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors

    5/1/23 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp

    9/8/22 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Financials

    Live finance-specific insights

    View All

    IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

    Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos

    6/2/25 7:30:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

    100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company devel

    2/11/25 8:00:00 AM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

    100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini

    6/13/24 4:01:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IN8bio Inc.

    SC 13D/A - IN8BIO, INC. (0001740279) (Subject)

    10/11/24 6:01:16 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by IN8bio Inc.

    SC 13G - IN8BIO, INC. (0001740279) (Subject)

    10/9/24 5:19:20 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by IN8bio Inc.

    SC 13G/A - IN8BIO, INC. (0001740279) (Subject)

    9/17/24 7:30:50 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care